A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors

2014 ◽  
Vol 20 (24) ◽  
pp. 6284-6294 ◽  
Author(s):  
L. Rhoda Molife ◽  
Emma Jane Dean ◽  
Montserrat Blanco-Codesido ◽  
Matthew G. Krebs ◽  
Andre T. Brunetto ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study ◽  
Receptor Tyrosine Kinase Inhibitor

P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S182
Author(s):  
Catherine Wheeler ◽  
Hironobu Minami ◽  
Hiromichi Ebi ◽  
Makoto Tahara ◽  
Yasutsuna Sasaki ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Receptor Tyrosine Kinase ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Vegf Receptor ◽  
Receptor Tyrosine Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document